Hosted on MSN19d
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...
Monthly Prescribing Reference23d
Calquence Combo Therapy Approved for Previously Untreated Mantle Cell Lymphoma
“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...
Managed Healthcare Executive12d
FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...